Seattle biotech co. to move to Houston thanks to $13.3M grant from Texas organization

CPRIT funding spotted

OncoResponse in partnership with MD Anderson Cancer Center received a portion of $73 million the Cancer Prevention and Research Institute of Texas has doled out this spring. Photo via oncoresponse.com

A biotech company has landed a more than $13 million grant from the Cancer Prevention and Research Institute of Texas.

The nearly $13.3 million grant given to OncoResponse — which is relocating from Seattle to Houston, according to CPRIT's news release — will help the company develop fully human monoclonal antibodies for treatment of cancer that otherwise would not respond to immunotherapy. OncoResponse already has a partnership with MD Anderson Cancer Center, which is one of the company’s investors.

“We are thrilled to receive this recognition from CPRIT in supporting the potential of our immunotherapy candidate OR502. We greatly appreciate the additional support from our investors as we continue to make significant progress with our drug development efforts advancing immunotherapies derived from clues of Elite Responders,” says Clifford Stocks, CEO of OncoResponse, in a news release.

Aside from the grant, OncoResponse just hauled in $14 million from existing investors in a round led by RiverVest Venture Partners. Other participants in the series D round include Venture Partners, Canaan Partners, 3B Future Health Fund, Bering Capital, Takeda Ventures, and InterVest Capital Partners.

To date, OncoResponse has raised more than $180 million, according to market research company CB Insights.

A representative of OncoResponse couldn’t be reached for comment about the company’s relocation to Houston.

MD Anderson and Seattle-based Theraclone Sciences launched OncoResponse in 2015. Rice University was among the inaugural investors.

OncoResponse’s OR2805 immunotherapy product is being evaluated in a Phase 1 clinical trial. It’s the company’s leading immunotherapy candidate. OncoResponse is also working on OR502, an antibody being prepared for investigational and clinical studies.

“The modern treatment of cancer activates the body’s own immune system to attack cancer,” OncoResponse says in a summary posted on the website of the Cancer Prevention and Research Institute of Texas (CPRIT).

“These treatments, called immunotherapy, may not be successful if the cancer can recruit bad-acting cells, such as tumor associated macrophages, or TAMs, that create barriers preventing immunotherapies from activating the body’s own defenses against the cancer. To find drugs that may help counteract these TAMs, OncoResponse looked to patients who had responded very well to immunotherapy to see if their bodies made factors to block TAMs and helped them fight their cancers.”

OncoResponse’s OR502 prevents TAMs from shutting down the body’s response to cancer, thus restoring tumor-killing immune activity, CPRIT explains.

In addition to OncoResponse, recent CPRIT grant recipients from the Houston area are:

  • Houston-based 7 Hills Pharma, $13,439,001. The company is working on immunotherapies for treatment of cancer and prevention of infectious diseases.
  • Houston-based Allterum Therapeutics, $11,721,150. The company is coming up with an antibody for treatment of patients with acute lymphoblastic leukemia. This type of cancer affects blood and bone marrow.
  • Houston-based Cell Therapy Manufacturing Center, $9.1 million. The center is a joint venture between National Resilience and MD Anderson Cancer Center that is developing cell therapy manufacturing technologies to support biotech partnerships.
  • Houston-based Pulmotect, $8,851,165. The company’s PUL-042 product is aimed at treating and preventing respiratory complications in cancer patients.
  • Cancer researcher Michael King, $6 million. The grant helped lure King to Rice from Nashville’s Vanderbilt University, where he’s been the chair of biomedical engineering. King’s lab at Vanderbilt has been testing therapies for metastatic breast cancer and prostate cancer.
  • Missouri City-based OmniNano Pharmaceuticals, $2,711,437. The pharmatech company is working on two drugs for treatment of solid tumors in patients with pancreatic cancer.

“Texas is unique because of CPRIT’s ability to invest in cutting-edge research when private capital is scarce. This is yet another way Texas is leading the nation in the fight against cancer,” Wayne Roberts, CEO of CPRIT, says in a news release.

From Your Site Articles
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

New York Stock Exchange Texas announces location for Dallas headquarters

NYSE Texas

A location has been chosen for The New York Stock Exchange Texas, the new Dallas-based offshoot of the The New York Stock Exchange in New York.

According to a release, the NYSE Texas has leased 28,000 square-feet of space at Old Parkland, the hospital-turned office space at 3819 Maple Ave. in Oak Lawn, where it will operate as a fully electronic equities exchange headquartered in Dallas. The property is owned by Dallas billionaire Harlan Crowe, who acquired it in 2006.

The NYSE is part of the Intercontinental Exchange, Inc., a global provider of technology and data. It was previously the NYSE Chicago, which will close once the bureau in Texas debuts.

They’ve also named a president to the Texas branch: Bryan Daniel, former chairman of the Texas Workforce Commission. In his new role over the NYSE Texas, Daniel will report to President of NYSE Group Lynn Martin.

Relocating from Chicago to Texas was a response to Texas' pro-business profile, Martin says in a statement.

“As the state with the largest number of NYSE listings, representing over $3.7 trillion in market value for our community, Texas is a market leader in fostering a pro-business atmosphere,” Martin says. “We are delighted to expand our presence in the Lone Star State, which plays a key role in driving our U.S. economy forward.”'

The move comes five months after the Texas Stock Exchange — AKA TXSE — announced plans to launch in Dallas and begin trading in 2026, pending approval from the U.S. Securities and Exchange Commission. The Texas Stock Exchange is backed by financial giants such as BlackRock, Citadel Securities, and Charles Schwab.

The NYSE expects the Texas location to open in 2026, where it will operate electronically, with stocks trading across multiple venues regardless of where they are first listed, according to the release.

---

This article originally appeared on CultureMap.com.

Houston energy giants rank high on new corporate startup activity report

startup support

Eight major players in Houston’s energy industry rank among the world’s top 20 energy companies for corporate startup activity.

The inaugural Corporate Startup Activity Index 2025, published by StartupBlink, ranks global corporations by industry. The eight Houston-area employers fall into the index’s energy and environment category.

Researchers from StartupBlink, an innovation research platform, scored more than 370 companies based on three factors: corporate involvement in startup activity, startup success and ecosystem integration.

The eight Houston-area energy employers that landed in the energy and environment category’s top 20 are:

  • No. 3 BP. Score: 13.547. U.S. headquarters in Houston.
  • No. 5 Saudi Aramco. Score: 7.405. Americas headquarters in Houston.
  • No. 7 Eni. Score: 6.255. Headquarters of Eni U.S. Operating Co. in Houston.
  • No. 8 Shell. Score: 6.217. U.S. headquarters in Houston.
  • No. 11 Occidental Petroleum. Score: 5.347. Global headquarters in Houston.
  • No. 15 Engie. Score: 3.352. North American headquarters in Houston.
  • No. 17 Repsol. Score: 2.980. U.S. headquarters for oil and gas operations in The Woodlands.
  • No. 19 Chevron. Score: 2.017. Global headquarters in Houston.

“Building a startup is hard, and navigating corporate innovation can be just as complex. This ranking is a step toward making the connection between startups and corporations more transparent, enabling startups and corporations to collaborate more effectively for mutual success,” said Eli David Rokah, CEO of StartupBlink.

Salesforce topped the global index with a score of 380.090, followed by Intel, Google, Qualcomm, and Comcast.

Houston researchers develop strong biomaterial that could replace plastic

plastic problem

Collaborators from two Houston universities are leading the way in engineering a biomaterial into a scalable, multifunctional material that could potentially replace plastic.

The research was led by Muhammad Maksud Rahman, an assistant professor of mechanical and aerospace engineering at the University of Houston and an adjunct assistant professor of materials science and nanoengineering at Rice University. The team shared its findings in a study in the journal Nature Communications earlier this month. M.A.S.R. Saadi, a doctoral student in material science and nanoengineering at Rice, served as the first author.

The study introduced a biosynthesis technique that aligns bacterial cellulose fibers in real-time, which resulted in robust biopolymer sheets with “exceptional mechanical properties,” according to the researchers.

Biomaterials typically have weaker mechanical properties than their synthetic counterparts. However, the team was able to develop sheets of material with similar strengths to some metals and glasses. And still, the material was foldable and fully biodegradable.

To achieve this, the team developed a rotational bioreactor and utilized fluid motion to guide the bacteria fibers into a consistent alignment, rather than allowing them to align randomly, as they would in nature.

The process also allowed the team to easily integrate nanoscale additives—like graphene, carbon nanotubes and boron nitride—making the sheets stronger and improving the thermal properties.

“This dynamic biosynthesis approach enables the creation of stronger materials with greater functionality,” Saadi said in a release. “The method allows for the easy integration of various nanoscale additives directly into the bacterial cellulose, making it possible to customize material properties for specific applications.”

Ultimately, the scientists at UH and Rice hope this discovery could be used for the “next disposable water bottle,” which would be made by biodegradable biopolymers in bacterial cellulose, an abundant resource on Earth.

Additionally, the team sees applications for the materials in the packaging, breathable textiles, electronics, food and energy sectors.

“We envision these strong, multifunctional and eco-friendly bacterial cellulose sheets becoming ubiquitous, replacing plastics in various industries and helping mitigate environmental damage,” Rahman said the release.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

View All Listings